All In Biotech

Drug Trial Radar · NCT01945710

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

62

Actual

Start

Dec 11, 2012

Primary completion

Oct 2015

Study completion May 17, 2016

Sponsor

Lead sponsor
Eisai LimitedEisai
Sponsor type
Industry
First posted
Sep 18, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study E7389-E044-112 is a Phase 1 study designed to assess the safety, tolerability and preliminary efficacy of eribulin-liposomal formulation (E7389-LF) in patients with solid tumors. This dose-escalation study will determine the maximum tolerated dose, dosing schedules tested, the dose schedule regimen with a more favorable tolerability profile, and a preliminary indication of efficacy.

Conditions

  • Solid Tumors

Interventions

  • Eribulin-LFDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) of Eribulin-LFTime frame: Schedule 1: Cycle 1 (21 days); Schedule 2: Cycle 1 (28 days)
  2. Dose Limiting Toxicities at the Indicated Dose Levels, as an Assessment of Dosing FrequencyTime frame: Cycle 1 of Dose Escalation part in Schedule 1 and Schedule 2

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • UCL Cancer Institute

    London, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • Royal Marsden Hospital

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.